• Бактеріальний вагіноз: сучасний погляд на проблему 
ua До змісту

Бактеріальний вагіноз: сучасний погляд на проблему 

HEALTH OF WOMAN.2015.4(100):32–40; doi 10.15574/HW.2015.100.32 
 

Бактеріальний вагіноз: сучасний погляд на проблему 
 

Товстановська В. О., Микитенко Н. М., Фаракак Парсай

Национальный медицинский университет им. А.А. Богомольца, г. Киев 
 

У статті висвітлено сучасні підходи до діагностики та лікування бактеріальних вагінозів. Наведено морфологічний поліморфізм і видова різноманітність збудників, що ускладнює проведення діагностики. Установлення діагнозу слід здійснювати підтверджуючи виявлення і типування збудника молекулярно-генетичними методами. На підставі аналізу даних наукової літератури виявлено, що терапія має бути спрямована на відновлення нормального мікроценозу і рН піхви. 
 

Ключові слова: бактеріальний вагіноз, діагностика, етіологія, лікування, Gardnerella vaginalis. 
 

Література: 

1. Тымченко ОИ, Лынчак ОВ, Процюк ОВ, Микитенко ДА и др. 2014. Репродуктивное поведение женщин в Украине. Вестник Витебского государственного медицинского университета 13;3:146–151.

2. Байрамова ГР. 2001. Бактериальный вагиноз. Практическая гинекология: сб. науч. ст. М:189–200.

3. Байрамова ГР. 1992. Клинические особенности и эффективность раличных методов терапии бактериального вагиноза. Дисс. канд. мед. наук. М.

4. Кира ЕФ. 2001. Бактериальный вагиноз. Санкт-Петебург:364.

5. Thomason JL, Gelbard SM, Scaglione NJ. 2001. Bacterial vaginosis: current rewiew with indications for asymptomatic therapy. Amer J Obstet Gynecol 165;4:1210–1217.

6. Глуховец НГ, Мезин ЕВ, Глуховец БИ. 2002. Значение восходящего инфицирования последа в патогенезе послеродовых эндометритов. Охрана здоровья матери и ребенка: Матер. 4-го Росс. науч. форума:89.

7. Тютюнник ВЛ. 2005. Патогенез, диагностика и методы лечения бактериального вагиноза. Фарматека 2(98):20–24.

8. Доброхотова ЮЭ, Затикян НГ. 2008. Современные представления о механизмах развития дисбиоза влагалища. Акушерство, гинекология и репродукция 1:7–9.

9. Giraldo PC et al. 2007. Freqьente desafio do entendimento e do manuseio da vaginose bacteriana. DST – Jornal Brasileiro de Doenзas Sexualmente Transmissнveis19;2:84–91. Rio de Janeiro.

10. Бодяжина ВИ. 1980. О барьерных механизмах половой системы женщины. Акушерство и гинекология 1:5–7.

11. Гриненко ГВ, Шалепо КВ, Шипицына ЕВ и др. 2003. Факторы риска развития урогенитальной инфекции у женщин. Журн. акуш. и женских болезней LII;2:95–100.

12. Долгушина ВФ, Долгушин ИИ. 2004. Инфекционная патология влагалища. Генитальные инфекции и патология шейки матки: клинические лекции. Под ред. ВН Прилепской, Рудаковой ЕБ. Омск:144–151.

13. Соловьева ИВ. 1987. Характеристика микрофлоры влагалища в норме и патологии: Автореф. дис. канд. мед. наук. М:17.

14. Trama JP, Pascal KE, Zimmerman J et al. 2008. Rapid detection of Atopobium vaginae and association with organisms implicated in bacterial vaginosis. Mol. Cell Probes. 22;2:96–102.

15. Schwebke JR, Desmond R. 2005. Risk factors for bacterial vaginosis in women at high risk for sexually transmitted diseasesю. Sexually Transmitted Diseases, Philadelphia. 32;11:654–658.

16. Байрамова ГР. 2004. Бактериальный вагиноз. Поликлиническая гинекология. Под ред. ВН Прилепской. М:126–134.

17. Белобородов СМ, Леонов БВ, Белобородова НВ и др. 2001. Метаболиты анаэробных бактерий (летучие жирные кислоты) в фолликулярной жидкости женщин, страдающих бесплодием. Акуш. и гин. 4:29–33.

18. Белянин ВЛ. 1998. Морфологическая диагностика причин и сроков давности воспалительного процесса при инфекциях: пособие для врачей. СПб:35.

19. Побединский НМ, Аксенова ОА, Аксенова МГ, Молочков ВА. 2006. Клинико-бактериологическое обоснование комплексного лечения бактериального вагиноза у женщин репродуктивного возраста. Акушерство и гинекология 6:24–27.

20. Сафронова ММ, Гренкова ЮМ. 2009. Нарушение влагалищного микробиоценоза: современные методы коррекции. Клин. дерматол. венерол. 6:23–25.

21. Bradshaw CS, Tabrizi SN, Fairley CK et al. 2006. The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. J. Infect. Disease. 194;6:828–836. http://dx.doi.org/10.1086/506621

22. Hale LP, Swidsinski A, Mendling W. 2006. Bacteria associated with bacterial vaginosis. N Engl J Med. 354;2:202–3. http://dx.doi.org/10.1056/NEJMc053336

23. Swidsinski A, Mendling W, Loening-Baucke V et al. 2008. An adherent Gardnerell avaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol 1:198:97e1-97e6.

24. Липова ЕВ, Болдырева МН, Витвицкая ЮГ. 2009. Новый высокочувствительный способ диагностики дисбаланса нормо- и условно-патогенной биоты у женщин на ранних стадиях. Consilium medicum 11;6:47–51.

25. Ehrstrom S, Daroczy K, Rylander E, Samuelsson C et al. 2010. Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. Microbes Infect 13. http://dx.doi.org/10.1016/j.micinf.2010.04.010

26. Klebanoff MA. 2004. Time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment. American Journal of Obstetrics and Gynecology, St. Louis. 190;2:363–370. http://dx.doi.org/10.1016/j.ajog.2003.08.020

27. Amsel R, Totten PA, Spiegel CA, Chen KC et al. 1983. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am. J. Med. 74;1:14–22. http://dx.doi.org/10.1016/0002-9343(83)91112-9

28. Gibbs RS. 2007. Asymptomatic bacterial vaginosis: is it time to treat? American Journal of Obstetrics and Gynecology, St. Louis. 196;6:495–496.

29. Donders GG. 1999. Bacterial vaginosis during pregnancy: screen and treat? European Journal of Obstetrics Gynecology and Reproductive Biology. Amsterdam. 83;1:1–4.

30. Тихомиров АЛ, Юдаев ВН, Лубнин ДМ. 2003. Современный алгоритм терапии воспалительных заболеваний половой системы. РМЖ (Русский медицинский журнал) 1:12–17.

31. De Backer E, Dubreuil L, Brauman M et al. 2010. In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis. Clin.Microbiol.Infect. 16;5:470–472. http://dx.doi.org/10.1111/j.1469-0691.2009.02852.x

32. Воронин КВ, Нахла БС, Чуйко ВИ и др. 2012. Бактериальный вагиноз беременных: этиологическая диагностика, прогнозирование и принципы активной профилактики инфекционных и перинатальных ослонений. Таврич. мед.-биолог. вестн. 15;2:40–43.

33. Чигринец ОВ. 2004. Этиологические и патогенетические аспекты, оптимизация диагностики и терапия хронических цервицитов. Дис. канд. мед. наук. Челябинск:174.

34. Прилепская ВН, Рудакова ЕБ, Кононов АВ. 2002. Эктопии и эрозии шейки матки. М, МЕДпресс-информ:176.

35. Роговская СИ, Прилепская ВН. 2002. Бактериальный вагиноз и папилломавирусная инфекция. Гинекология 3:126–130.

36. Thulkar J, Kriplani A, Agarwal N. 2012. A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis. Indian J. Pharmacol. 44;2:243–245. http://dx.doi.org/10.4103/0253-7613.93859

37. Мурашко МА, Воронова СИ. 2002. Механизм дородового излития околоплодных вод при бактериальном вагинозе. Мать и дитя: Матер. 4-го Росс. Форума. М. 1:420.

38. Ефимов БА, Тютюнник ВЛ. 2008. Бактериальный вагиноз: современный взгляд на проблему. РМЖ 16(1):18–23.

39. Baloрlu E, Ozyazici M, Baloрlu A, Ova L. 2003. A randomized controlled trial of a new ovule formulation of ornidazole for the treatment of bacterial vaginosis. J. Clin. Pharm. Ther. 28;2:131–136. http://dx.doi.org/10.1046/j.1365-2710.2003.00472.x

40. Haggerty CL et al. 2004. Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clinical Infectious Diseases. Chicago. 39;7:990–995. http://dx.doi.org/10.1086/423963; PMid:15472851

41. Ness RB et al. 2004. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstetrics and Gynecology, Hagerstown. 104;4:761–769. http://dx.doi.org/10.1097/01.AOG.0000139512.37582.17; PMid:15458899

42. Schwebke JR. 2009. New concepts in the etiology of bacterial vaginosis. Current Infectious Disease Reports, Philadelphia. 11;2:143–147. http://dx.doi.org/10.1007/s11908-009-0021-7

43. Hasenack BS et al. 2008. Comparative study for the diagnosis of bacterial vaginosis by Papanicolaou and Gram staining techniques. Revista Brasileira de Anбlises Clнnicas, Rio de Janeiro. 40;2:159–162.

44. Sha BE, Chen HY, Wang QJ et al.. 2005. Utility of Amsel criteria, Nugent score, and quantitative PCR for Gardnerella vaginalis, Mycoplasma hominis, and Lactobacillus spp. for diagnosis of bacterial vaginosis in human immunodeficiency virus-infected women. J. Clin.Microbiol. 43;9:4607–4612.

45. Workowski KA, Berman SM. 2006. Sexually transmitted diseases treatment guidelines. MMWR Recomm.Rep. 55(RR-11):1–94.

46. Figueiredo PG. Reduзгo da expressгo da ciclo-oxigenase-2 em lesхes precursoras do cвncer do colo uterino em mulheres com vaginose bacteriana. 2006. Tese (Doutoradoem Tocoginecologia), Faculdade de Ciкncias Mйdicas, Universidade Estadual de Campinas, SP.

47. Nugent RP, Krohn MA, Hillier SL. 1991. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. Journal of Clinical Microbiology. Washington. 29;2:297–301.

48. Spiegel CA, Amsel R, Holmes KK. 1983. Diagnosis of bacterial vaginosis by direct gram stain of vaginal fluid. J Clin Microbiol. 18;170–177.

49. Forsum U, Larsson PG, Spiegel C. 2008. Scoring vaginal fluid smears for diagnosis of bacterial vaginosis: need for quality specifications. APMIS. 116;2:156–159. http://dx.doi.org/10.1111/j.1600-0463.2008.00984.x; PMid:18321368

50. Forsum U, Jakobsson T, Larsson PG et al. 2002. An international study of the interobserver variation between interpretations of vaginal smear criteria of bacterial vaginosis. APMIS. 110;11:811–818. http://dx.doi.org/10.1034/j.1600-0463.2002.1101107.x

51. Larsson PG, Carlsson B, Fahraeus L, Jakobsson T et al. 2004. Diagnosis of bacterial vaginosis: need for validation of microscopic image area used for scoring bacterial morphotypes. Sex Transm. Infect. 80;1:63–67. http://dx.doi.org/10.1136/sti.2003.006106; PMCid:PMC1758394

52. Hoyme UB, Saling E. 2004. Efficient prematurity prevention is possible by pH-self meas urement and immediate therapy of threatening ascending infection. Eur. J. Obstet. Gynecol. Reprod.Biol. 115;2:148–153.

53. Thomason JL, Gelbart SM, James JA, Edwards JM et al. 1988. Is analysis of vaginal secretions for volatile organic acids to detect bacterial vaginosis of any diagnostic value? Am. J. Obstet. Gynecol. 159;6:1509–1511. http://dx.doi.org/10.1016/0002-9378(88)90585-6

54. Chandiok S, Crawley BA, Oppenheim BA, Chadwick PR et al. 1997. Screening for bacterial vaginosis: a novel application of artificial nose technology. J. Clin.Pathol. 50;9:790–791. http://dx.doi.org/10.1136/jcp.50.9.790

55. Hay P, Tummon A, Ogunfile M, Adebiyi A et al. 2003. Evaluation of a novel diagnostic test for bacterial vaginosis: ‘the electronic nose’. Int. J. STD AIDS. 14;2:114–118. http://dx.doi.org/10.1258/095646203321156881; PMid:12662390

56. West B, Morison L, Schim van der Loeff M et al. 2003. Evaluation of a new rapid diagnostic kit (FemExam) for bacterial vaginosis in patients with vaginal discharge syndrome in The Gambia. Sex.Transm. Dis. 30;6:483–489. http://dx.doi.org/10.1097/00007435-200306000-00003

57. Reid G, Burton J, Hammond JA, Bruce AW. 2004. Nucleic acid-based diagnosis of bacterial vaginosis and improved management using probiotic lactobacilli. J. Med. Food. 7;2:223–228. http://dx.doi.org/10.1089/1096620041224166; PMid:15298771

58. Posner SF, Kerimova J, Aliyeva F, Duerr A. 2005. Strategies for diagnosis of bacterial vaginosis in a resource-poor setting. Int. J. STD AIDS. 16;1:52–55. http://dx.doi.org/10.1258/0956462052932601

59. Myziuk L, Romanowski B, Johnson SC. 2003. BVBlue test for diagnosis of bacterial vaginosis. J. Clin.Microbiol. 41;5:1925–1928. http://dx.doi.org/10.1128/JCM.41.5.1925-1928.2003; PMCid:PMC154737

60. Bradshaw CS, Morton AN, Garland SM, Horvath LB et al. 2005. Evaluation of a point-of-care test, BVBlue, and clinical and laboratory criteria for diagnosis of bacterial vaginosis. J. Clin.Microbiol. 43;3:1304–1308. http://dx.doi.org/10.1128/JCM.43.3.1304-1308.2005; PMid:15750100 PMCid:PMC1081297

61.Sumeksri P, Koprasert C, Panichkul S. 2005. BVBLUE test for diagnosis of bacterial vaginosis in pregnant women attending antenatal care at Phramongkutklao Hospital. J. Med. Assoc. Thai. 88 (Suppl.3):S7–S13.

62. Schoonmaker JN, Lunt BD, Lawellin DW, French JI et al. 1991. A new proline aminopeptidase assay for diagnosis of bacterial vaginosis. Am. J. Obstet. Gynecol. 165;3:737–742. http://dx.doi.org/10.1016/0002-9378(91)90320-Q

63. Nelson GH, Bacon J.L. 1994. Correlation between the clinical diagnosis of bacterial vaginosis and the results of a proline aminopeptidase assay. Infect. Dis. Obstet. Gynecol. 1;4:173–176.

64. Calderon E, Rivera R, Gordillo S, Conde-Glez C. 1997. Evaluation of a fast test to identify the presence of proline aminopeptidase in women with bacterial vaginosis. Infect. Dis. Obstet. Gynecol. 5;3:226–231. http://dx.doi.org/10.1002/(SICI)1098-0997(1997)5:3<226::AID-IDOG7>3.0.CO;2-Bhttp://dx.doi.org/10.1155/S1064744997000380http://dx.doi.org/10.1002/(SICI)1098-0997(1997)5:3<226::AID-IDOG7>3.3.CO;2-2

65. Briselden AM, Hillier SL. 1994. Evaluation of affirm VP microbial identification test for Gardnerella vaginalis and Trichomonas vaginalis. J. Clin. Microbiol. 32;1:148–152.

66. Obata-Yasuoka M, Ba-Thein W, Hamada H, Hayashi H. 2002. A multiplex polymerase chain reaction-based diagnostic method for bacterial vaginosis. Obstet. Gynecol. 100;4:759–764. http://dx.doi.org/10.1016/S0029-7844(02)02201-9

67. Schwebke JR, Lawing LF. 2001. Prevalence of Mobiluncus spp among women with and without bacterial vaginosis as detected by polymerase chain reaction. Sex. Transm. Dis. 28;4:195–199.

68. Zariffard MR, Saifuddin M, Sha BE, Spear GT. 2002. Detection of bacterial vaginosis-related organisms by real-time PCR for Lactobacilli, Gardnerella vaginalis and Mycoplasma hominis. FEMS Immunol Med. Microbiol. 34;4:277–281. http://dx.doi.org/10.1111/j.1574-695X.2002.tb00634.x

69. Burton JP, Chilcott CN, Al-Qumber M et al. 2005. A preliminary survey of Atopobium vaginae in women attending the Dunedin gynaecology out-patients clinic: is the contribution of the hard-to-culture microbiota overlooked in gynaecological disorders? Aust. NZ J. Obstet. Gynaecol. 45;5:450–452. http://dx.doi.org/10.1111/j.1479-828X.2005.00456.x; PMid:16171487

70. Ferris MJ, Masztal A, Martin DH. 2004. Use of species-directed 16S rRNA gene PCR primers for detection of Atopobium vaginae in patients with bacterial vaginosis. J. Clin. Microbiol. 42;12:5892–5894. http://dx.doi.org/10.1128/JCM.42.12.5892-5894.2004; PMid:15583334 PMCid:PMC535275

71. Fredricks DN, Fiedler TL, Marrazzo JM. 2005. Molecular identification of bacteria associated with bacterial vaginosis. N. Engl. J. Med. 353;18:1899–1911. http://dx.doi.org/10.1056/NEJMoa043802 
PMid:16267321

72. Verhelst R, Verstraelen H, Claeys G et al. 2004. Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between Atopobium vaginae, Gardnerella vaginalis and bacterial vaginosis. BMC Microbiol. 4:16.

73. Verhelst R, Verstraelen H, Claeys G et al. 2005. Comparison between Gram stain and culture for the characterization of vaginal microflora: definition of a distinct grade that resembles grade I microflora and revised categorization of grade I microflora. BMC Microbiol. 5:61.

74. De Backer E, Verhelst R, Verstraelen H et al. 2007. Quantitative determination by real-time PCR of four vaginal Lactobacillus species, Gardnerella vaginalis and Atopobium vaginae indicates an inverse relationship between L. gasseri and L. Iners. BMC Microbiol. 7:115.

75. Tamrakar R, Yamada T, Furuta I et al. 2007. Association between Lactobacillus species and bacterial vaginosis-related bacteria, and bacterial vaginosis scores in pregnant Japanese women. BMC Infect.Dis. 7:128.

76. Verstraelen H, Verhelst R, Claeys G, De Backer E et al. 2009. Longitudinal analysis of the vaginal microflora in pregnancy suggests that L. crispatus promotes the stability of the normal vaginal microflora and that L. gasseri and/or L. iners are more conducive to the occurrence of abnormal vaginal microflora. BMC Microbiol. 9$1:116.

77. Centers for Disease Control: Sexually transmitted diseases. 1998, MMWR. 28(4):61–63.

78. Klatt TE, Cole DC, Eastwood DC, Barnabei VM. 2010. Factors associated with recurrent bacterial vaginosis. J Reprod Med. 55(1–2):55–61.

79. De Backer E, Verhelst R, Verstraelen H et al. 2006. Antibiotic susceptibility of Atopobium vaginae. BMC Infect.Dis. 6:51.

80. McMillan A, Dell M, Zellar MP et al. 2011. Disruption of urogenital biofilms by Lactobacilli. Colloids Surf B Biointerfaces. 86:58–64. http://dx.doi.org/10.1016/j.colsurfb.2011.03.016; PMid:21497071

81. Межевитинова ЕА, Бровкина ТВ, Довлетханова ЭР. 2012. ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова Минздрава РФ. М. Бактериальный вагиноз: как снизить число рецидивов? Гинекология 4.

82. Ventolini G, Villa I, Guerra A. 1987. A controlled clinical study on the efficacy of benzydamine in the topical treatment of non-specific cervicitis and vaginitis. Int. J. Tissue React. 9;2:157–167.

83. Ison CA, Taylor RF, Link C, Buckett P et al. 1987. Local treatment for bacterial vaginosis. Br. Med. J. (Clin. Res. Ed.) 295(6603):886.

84. Molteni B, D’Antuono A, Bandini P et al. 2004. Efficacy and tolerability of a new chlorhexidine-based vaginal gel in vaginal infections. Curr. Med. Res. Opin. 20;6:849–853. http://dx.doi.org/10.1185/030079904125003692; PMid:15200742

85. Petersen EE, Weissen-bacher ER, Hengst P et al. 2002. Local treatment of vaginal infections of varying etiology with dequalinium chloride or povidone iodine. A randomised, double-blind, active-controlled, multicentric clinical study. Arzneimit-telforschung. 52;9:706–715.

86. Gerli S, Rossetti D, Di Renzo GC. 2003. A new approach for the treatment of bacterial vaginosis: use of polyhexamethylene biguanide. A prospective, randomized study. Eur. Rev. Med. Pharmacol. Sci. 7;5:127–130.

87. Minozzi M, Gerli S, Di Renzo GC, Papaleo E et al. 2008. The efficacy and safety of a single dose of polyhexamethylene biguanide gynaecologic solution versus a seven-dose regimen of vaginal clindamycin cream in patients with bacterial vaginosis. Eur. Rev. Med. Pharmacol. Sci. 12;1:59–65.

88. Dattani IM, Gerken A, Evans BA. 1982. Aetiology and management of non-specific vaginitis. Br. J. Vener. Dis. 58;1:32–35. http://dx.doi.org/10.1136/sti.58.1.32

89. Wewalka G, Stary A, Bosse B, Duerr HE et al. 2002. Efficacy of povidone-iodine vaginal suppositories in the treatment of bacterial vaginosis. Dermatology. 204(Suppl.1): 79–85.

90. Yu H, Tak-Yin M. 1993. The efficacy of povidone-iodine pessaries in a short, low-dose treatment regime on candidal, trichomonal and non-specific vaginitis. Postgrad. Med. J. 69(Suppl. 3):S58–S61.

91. Winceslaus SJ, Calver G. 1996. Recurrent bacterial vaginosis – an old approach to a new problem. Int. J. STD AIDS. 7;4:284–287.

92. Cardone A, Zarcone R, Borrelli A, Di Cunzolo A et al. 2003. Utilisation of hydrogen peroxide in the treatment of recurrent bacterial vaginosis. Minerva Ginecol. 55;6:483–492.

93. Petersen EE. 1998. Der Einsatz von Vitamin C (Vagi-C) zur Normalisierung der Vaginalflora. Gyne. 19.

94. Polatti F, Rampino M, Magnani P, Mascarucci P. 2006. Vaginal pH lowering effect of a vaginal tablet, containing 250 mg of Vitamin C, in subjects with high vaginal pH. Gynecol Endocrinol. 22;4:230–4. http://dx.doi.org/10.1080/09513590600647441; PMid:16723311

95. Громова ОА, Торшин ИЮ, Гарасько ЕА. 2010. Молекулярные механизмы топического назначения витамина С в лечении бактериального вагиноза. Акуш. и гинекол. 11:37–42.

96. Boeke J et al. 1993. Effect of lactic acid suppositories compared with oral metronidazole and placebo in bacterial vaginosis: a randomized clinical. Genitourin Med. 69;5:388–92. http://dx.doi.org/10.1136/sti.69.5.388

97. Senok A, Verstraelen H, Temmerman M, Botta G. 2006. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst. Rev. (Issue 4. Art. No.: CD006289)

98. Parent D, Bossens M, Bayot D et al. 1996. Therapy of bacterial vaginosis using exogenously-applied Lactobacilli acidophili and a low dose of estriol: a placebo-controlled multicentric clinical trial. Arzneimittelforschung 46;1:68–73.

99. Eriksson K, Carlsson B, Forsum U, Larsson PG. 2005. A double-blind treatment study of bacterial vaginosis with normal vaginal lactobacilli after an open treatment with vaginal clindamycin ovules. Acta. Derm. Venereol. 85;1:42–46. http://dx.doi.org/10.1080/00015550410022249; PMid:15848990

100. Anukam K, Osazuwa E, Ahonkhai I et al. 2006. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect. 8;6:1450–1454. http://dx.doi.org/10.1016/j.micinf.2006.01.003; PMid:16697231

101. Anukam KC, Osazuwa E, Osemene GI, Ehigiagbe F et al. 2006. Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect. 8(12–13):2772–2776.

102. Larsson PG, Stray-Pedersen B, Ryttig KR, Larsen S. 2008. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health 8;3.

103. Mastromarino P, Macchia S, Meggiorini L et al. 2009. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin. Microbiol. Infect. 15;1:67–74. http://dx.doi.org/10.1111/j.1469-0691.2008.02112.x; PMid:19046169

104. Marcone V, Calzolari E, Bertini M. 2008. Effectiveness of vaginal administration of Lactobacillus rhamnosus following conventional metronidazole therapy: how to lower the rate of bacterial vaginosis recurrences. New Microbiol. 31;3:429–433.

105. Reichman O, Akins R, Sobel JD. 2009. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm.Dis. (Epub ahead of print).

106. Vutyavanich T, Pongsuthirak P, Vannareumol P, Ruangsri RA, Luangsook P. 1993. A randomized double-blind trial of tinidazole treatment of the sexual partners of females with bacterial vaginosis. Obstet. Gynecol. 82(4;1):550–554.

107. Swedberg J, Steiner JF, Deiss F, Steiner S, Driggers DA. 1985. Comparison of single-dose vs one-week course of metronidazole for symptomatic bacterial vaginosis. JAMA. 254;8:1046–1049. http://dx.doi.org/10.1001/jama.1985.03360080058029http://dx.doi.org/10.1001/jama.254.8.1046

108. Vejtorp M, Bollerup AC, Vejtorp L et al. 1988. Bacterial vaginosis: a double-blind randomized trial of the effect of treatment of the sexual partner. Br. J. Obstet. Gynaecol. 95;9:920–926. http://dx.doi.org/10.1111/j.1471-0528.1988.tb06581.x

109. Moi H, Erkkola R, Jerve F et al. 1989. Should male consorts of women with bacterial vaginosis be treated? Genitourin. Med. 65;4:263–268.

110. Colli E, Landoni M, Parazzini F. 1997. Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial. Genitourin. Med. 7;4:267–270. http://dx.doi.org/10.1136/sti.73.4.267

111. Potter J. 1999. Should sexual partners of women with bacterial vaginosis receive treatment? Br. J. Gen. Pract. 49;448:913–918.

112. Hutchinson KB, Kip KE, Ness RB. 2007. Condom use and its association with bacterial vaginosis and bacterial vaginosis-associated vaginal microflora. Epidemiology 18;6:702–708. http://dx.doi.org/10.1097/EDE.0b013e3181567eaa; PMid:17917605

113. Yotebieng M, Turner AN, Hoke TH, Van Damme K et al. 2009. Effect of consistent condom use on 6-month prevalence of bacterial vaginosis varies by baseline BV status. Trop. Med. Int. Health 14;4:480–486. http://dx.doi.org/10.1111/j.1365-3156.2009.02235.x; PMid:19222825